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Second generation antipsychotics (SGAs) have been linked to metabolic and bone disorders in clinical studies,
but the mechanisms of these side effects remain unclear. Additionally, no studies have examined whether
SGAs cause bone loss in mice. Using in vivo and in vitromodeling we examined the effects of risperidone, the
most commonly prescribed SGA, on bone in C57BL6/J (B6) mice. Mice were treated with risperidone orally by
food supplementation at a dose of 1.25 mg/kg daily for 5 and 8 weeks, starting at 3.5 weeks of age.
Risperidone reduced trabecular BV/TV, trabecular number and percent cortical area. Trabecular histomor-
phometry demonstrated increased resorption parameters, with no change in osteoblast number or function.
Risperidone also altered adipose tissue distribution such that white adipose tissue mass was reduced and liver
had signiﬁcantly higher lipid inﬁltration. Next, in order to tightly control risperidone exposure, we
administered risperidone by chronic subcutaneous infusion with osmotic minipumps (0.5 mg/kg daily for
4 weeks) in 7 week old female B6 mice. Similar trabecular and cortical bone differences were observed
compared to the orally treated groups (reduced trabecular BV/TV, and connectivity density, and reduced
percent cortical area) with no change in body mass, percent body fat, glucose tolerance or insulin sensitivity.
Unlike in orally treated mice, risperidone infusion reduced bone formation parameters (serum P1NP, MAR
and BFR/BV). Resorption parameters were elevated, but this increase did not reach statistical signiﬁcance. To
determine if risperidone could directly affect bone cells, primary bone marrow cells were cultured with
osteoclast or osteoblast differentiation media. Risperidone was added to culture medium in clinically relevant
doses of 0, 2.5 or 25 ng/ml. The number of osteoclasts was signiﬁcantly increased by addition in vitro of
risperidone while osteoblast differentiation was not altered. These studies indicate that risperidone treatment
can have negative skeletal consequences by direct activation of osteoclast activity and by indirect non-cell
autonomous mechanisms. Our ﬁndings further support the tenet that the negative side effects of SGAs on
bone mass should be considered when weighing potential risks and beneﬁts, especially in children and
adolescents who have not yet reached peak bone mass.
This article is part of a Special Issue entitled: Interactions Between Bone, Adipose Tissue and Metabolism.
© 2011 Elsevier Inc. All rights reserved.
Introduction
Second-generation antipsychotics (SGAs) are used to treat major
psychiatric disorders in part due to their lower incidence of
extrapyramidal side effects compared to ﬁrst-generation antipsy-
chotics (FGAs) [1]. Risperidone is one such SGA that is currently
indicated for use in adolescents (as young as 10) and adults with
schizophrenia and bipolar disorders, although it is widely used for
attention deﬁcit disorders. Risperidone is also approved for use in
children as young as 5 years old for treatment of irritability
associated with autism. Even though SGAs are highly prescribed,
they have been linked to metabolic disorders including obesity,
hyperglycemia and dyslipidemia [2–4]. The mechanism of metabolic
changes associated with antipsychotics is unknown, but it is clear
that a single dose (intravenous or intracerebroventricular) of certain
SGAs (olanzapine, clozapine, and to a lesser degree risperidone) can
dramatically reduce insulin sensitivity in the liver and this effect
continues after multiple doses [5]. Additionally, SGA-linked obesity
and type 2 diabetes mellitus are more prevalent in children and
adolescents [6–8].
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The relationship among energy metabolism, insulin signaling and
bone remodeling is becoming more apparent, so it is likely that drugs
that alter energy metabolism will ultimately affect bone mineral
density [9]. Indeed, clinical studies demonstrate reduced bone
mineral density and increased fracture risk in patients treated with
risperidone and other SGAs, although these studies are confounded by
indication (since the underlying disorders treated with antipsychotic
medication can be associated with reduced bone mineral density in
some cohorts) [10–16]. Risperidone can induce hyperprolactinemia
by dopamine receptor blockade and this can lead to hypothalamic
hypogonadism, which has been suggested as a possible mechanism of
bone loss [11,12,15,17]. However, a recent study demonstrated that
less than half of the patients using risperidone developed hyperpro-
lactinemia [11]. In addition, the increase in prolactin serum levels due
to risperidone treatment is often a temporary event [18]. Moreover,
unlike FGAs that bind mainly dopamine (D2) receptors, SGAs bind to
multiple targets, including serotonin (5-HT), histamine, and D2
receptors, and therefore can affect additional organ systems that
indirectly impact skeletal remodeling.
Despite some evidence that SGAs have a deleterious effect on bone,
rodent studies involving SGA administration have focused on
prolactin and the major metabolic consequences including weight
gain, fat redistribution and glucose intolerance. However, no studies
have examined whether risperidone is capable of causing direct
deleterious effects on bone, nor have any studies been reported in
mice. Here, we examined the effects of risperidone on bone and
adipose tissue metabolism, and found signiﬁcant trabecular and
cortical bone loss independent of weight gain and overt metabolic
dysfunction using two methods of risperidone administration (orally
in food and by subcutaneous infusion). Reduced trabecular bone mass
in mice fed a diet containing risperidone was due to increased
resorption, an effect that can be recapitulated by direct risperidone
administration to primary bone marrow derived osteoclasts in vitro.
On the other hand, chronic infusion of risperidone suppressed bone
formation, and showed a trend toward increased resorption,
indicating that the mode of delivery and age of mice are important
variables. Despite these differences, we have clearly established a
negative role for risperidone on bone metabolism through both direct
and indirect mechanisms.
Materials and methods
The experimental protocols were approved by the Institutional
Animal Care and Use Committee of the Maine Medical Center
Research Institute. The animals were maintained on 12 h light/12 h
dark cycles. The mice had free access to water and food.
Mice — oral risperidone administration
Male C57BL/6J (B6) mice were obtained from The Jackson
Laboratory (Bar Harbor, ME) at 3 weeks of age. Mice were fed normal
laboratory chow until 3.5 weeks of age, when they were switched to
wet mash supplemented with risperidone such that the dose
delivered was 1.25 mg/kg/day or control wet mash. Food intake was
monitored twice per week to ensure correct dosing. Mice were
maintained on risperidone or control diet for ﬁve (n=8 control,
8 risperidone) or 8 weeks (n=8 control, 8 risperidone), at which time
mice were euthanized and tissues were collected after an overnight
fast. Livers were stained for lipid deposition with Oil Red O.
Mice — risperidone infusion
Female C57BL6/J mice were purchased from The Jackson Labora-
tory (Bar Harbor, ME) at 6 weeks of age. At 7 weeks of age, mice were
implanted with Alzet Osmotic Minipumps (Durect Corporation,
Cupertino, CA) containing either 0.5 mg/kg/day risperidone (Sigma,
St. Louis, MO) or vehicle in the subcutaneous region dorsal to the right
hip. Concentration of risperidone was based on the average weight of
C57BL/6 female mice from 7 to 11 weeks of age. After 4 weeks of
risperidone or vehicle infusion mice were euthanized and tissues
collected after an overnight fast.
Dual-energy X-ray absorptiometry (DXA)
Control and risperidone treatedmice weremeasured at the time of
harvest for lean muscle mass, fat, and bone mineral density using the
PIXImus dual-energy X-ray densitometer (GE-Lunar, Madison, WI,
USA). The PIXImus was calibrated daily with a mouse phantom
provided by the manufacturer. Mice were placed ventral side down
with each limb and tail positioned away from the body. Full body
scans were obtained, and X-ray absorptiometry data were gathered
and processed with the manufacturer's supplied software (Lunar
PIXImus 2, version 2.1). The head was speciﬁcally excluded from all
analyses due to concentrated mineral in skull and teeth.
Micro-computed tomography (μCT)
Micro-architecture of the distal trabecular bone and midshaft
cortical bone of the femur were analyzed by μCT (resolution 10 μm,
VivaCT-40, Scanco Medical AG, Bassersdorf, Switzerland). Bones were
scanned at energy level of 55 kVp, and intensity of 145 μA. The
VivaCT-40 is calibrated weekly using a phantom provided by Scanco.
Trabecular bone volume fraction and micro-architecture were
evaluated in the secondary spongiosa, starting proximately at
0.6 mm proximal to the distal femoral growth plate, and extending
proximally 1.5 mm. Approximately 230 consecutive slices were made
at 10.5 μm interval at the distal end of the growth plate and extending
in a proximal direction, and 180 contiguous slices were selected for
analysis. Measurements included bone volume/total volume (BV/TV),
trabecular number (Tb.N.), trabecular thickness (Tb.Th.) and trabec-
ular separation (Tb.Sp.). Scans for the cortical region were measured
at the mid-point of each femur, with an isotropic pixel size of 21 μm
and slice thickness of 21 μm, and used to calculate the average bone
area (BA), total cross-sectional area (TA), bone area/total area (BA/
TA), and cortical thickness (Ct.Th.). For mid-shaft analysis, the cortical
shell was contoured by user-deﬁned threshold and iterated across the
50 slices. All scans were analyzed using a manufacturer software
(Scanco, version 4.05).
Histology and quantitative histomorphometry
Qualitative histologic analysis and quantitative static and dynamic
histomorphometry were performed as described previously [19]. To
examine bone-formation rates, calcein label (20 mg/kg) and deme-
clocycline label (20 mg/kg) were injected intraperitoneally at 9 and
2 days prior to euthanization, respectively. Immediately after eutha-
nization, tibias for histomorphometry were placed in 70% ethanol and
maintained in the dark at 4 °C. Histomorphometric measurements
were performed on the secondary spongiosa of the proximal tibia
metaphysis using an OsteoMeasure morphometry system (Osteo-
metrics, Atlanta, GA, USA). For dynamic histomorphometry, mineral-
izing surface per bone surface (MS/BS, %) and mineral apposition rate
(MAR, μm/day) were measured in unstained sections under ultravi-
olet (UV) light and used to calculate bone-formation rate with a
surface referent (BFR/BS, μm3/μm2/year), volume referent (BFR/BV,
%/year) and tissue referent (BFR/TV, %/year). Static measurements
included BV/TV (%), trabecular thickness (Tb.Th, μm), trabecular
number (Tb.N, /mm), trabecular separation (Tb.Sp, μm), eroded
surface per bone surface (ES/BS, %), osteoid surface per bone surface
(OS/BS, %), osteoid volume per tissue volume (OV/TV, %), osteoid
thickness (O.Th, μm), osteoblast surface per bone surface (Ob.S/BS, %),
osteoclast surface per bone surface (Oc.S/BS, %), osteoblast number
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per bone perimeter (N.Ob/B.Pm, /mm), osteoblast number per tissue
area (N.Ob/T.Ar, /mm2), osteoclast number per bone perimeter
(N.Oc/B.Pm, /mm), osteoclast number per tissue area (N.Oc/T.Ar,
/mm2), and adipocytes per total area (/mm2). Terminology and units
followed the recommendations of the Histomorphometry Nomencla-
ture Committee of the American Society for Bone and Mineral
Research [20].
Magnetic resonance imaging
Axial and coronal images were acquired in a 7.0 T Bruker
PharmaScan magnet. The animals were anesthetized with inhaled
isoﬂurane 1%, 0.4 l/min. The infused volume was adjusted, occasion-
ally, depending on animal respiration frequency. The acquisition
method used for body fat was: TR 600 ms, TE 87 ms, FOV
40×40×10 mm, matrix size 256×256×32, slice thickness 10 mm, 1
slice¸ no fat suppression, 4 average, with total scan time of about
11 min. For single pulse spectroscopy: TR 1000 ms, no fat suppression,
400 averages, with total scan time of about 7 min. Spectroscopy was
carried out by using the following parameters: TR=2500 ms,
TE=20 ms, voxel=0.75×7×0.75 mm, no fat suppression, 400
averages, with total scan time about 17 min.
Serum measurements
Serum adiponectin was measured with the Mouse Adiponectin
Assay Kit (Meso Scale Discovery, Gaithersburg, MD). Serum prolactin
was measured with the Mouse/Rat Prolactin Kit (Calbiotech, Spring
Valley, CA). Serum P1NP and CTx were measured with the Rat/Mouse
P1NP EIA and the RatLaps EIA, respectively (Immunodiagnostic
Systems, Scottsdale, AZ).
Insulin and glucose tolerance
For the insulin tolerance test (ITT), mice were fed ad libitum and
injected I.P. with insulin at a dose of 1 U/kg. Glucose levels were then
measured at 0, 20, 40, 60, 100, 120 and 150 min post injection. For the
glucose tolerance test (GTT), mice were placed in a clean cage with
water and fasted overnight (16 h). A 1 g/kg dose of glucose was
administered I.P. and blood glucose levels were measured at 0, 20, 40,
60, 80, 100, 120, 150 and 180 min post injection. Glucose levels were
measured using the OneTouch Ultra Glucometer (LifeScan, Inc.,
Milpitas, California, USA) per manufacturer's instructions.
Mass spectrometry
Risperidone and the active metabolite 9-OH risperidone levels were
measured by mass spectrometry in serum as previously shown [21].
Osteoclast culture
Whole bone marrowwas isolated from 8 week old female C57BL6/J
mice and plated in 96-well plates at a density of 2×106 cells/well and
cultured in the presence of RANKL and M-CSF as previously described
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Fig. 2. Reduced trabecular and cortical bone mass in the femur after 8 weeks of
risperidone administration. Shown are representative three-dimensional μCT images
from control and risperidone treated mice.
0
4
8
12
16
20
24
28
Bo
dy
 M
as
s 
(g)
*
0
5
10
15
20
25
*
*
%
 B
od
y 
Fa
t
0
4
8
12
16
20
24
Le
an
 M
as
s 
(g)
0
0.01
0.02
0.03
0.04
0.05
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
5 wk 8 wk5 wk 8 wk
5 wk 8 wk 5 wk 8 wk
5 wk 8 wk
To
ta
l a
BM
D
 (g
/cm
2 ) 
Fe
m
ur
 a
BM
D
 (g
/cm
2 ) 
*
Control Diet
Risperidone Diet
*p<0.05
Fig. 1. Reduced body fat and femur areal bone mineral density after risperidone administration. Risperidone was administered to male B6 mice orally in the food for ﬁve or 8 weeks,
starting at 3.5 weeks of age. Lean mass, fat mass, total and femur areal BMD were measured by DXA. Bars represent mean±standard error of untreated (white) and risperidone
treated mice (black). n=8. *pb0.05 by Student's t-test.
492 K.J. Motyl et al. / Bone 50 (2012) 490–498
[22]. Five replicateswere performedper experiment. Risperidone (0, 2.5
or 25 ng/ml) was added with each media change at days 0, 3 and 6.
Osteoclasts were harvested at day 7 by ﬁxation with 2.5% glutaralde-
hyde and stained for TRAP (Sigma Kit, St. Louis, MO). TRAP positive
osteoclasts with three or more nuclei were counted.
Statistical analyses
All data is presented as mean±standard error. Statistical signiﬁ-
cancewas determined using a two-tailed Student's t-test (alpha=0.05)
with Microsoft Excel (Microsoft, Redmond, WA).
Results
Oral risperidone administration
Risperidone was administered to male 3.5 week old B6 mice at a
dose of 1.25 mg/kg per day in the food to examine its effects on bone
metabolism. Risperidone fedmice had signiﬁcantly lower body weights
and lower body fat compared to controls after 5 weeks of treatment
(Fig. 1). After 8 weeks, the lower body fat remained statistically
signiﬁcant but there was no signiﬁcant difference in body mass.
Although there was no detectable difference in total aBMD by DXA at
either time point, risperidone-fed mice had signiﬁcantly lower femur
aBMD after 8 weeks of treatment compared to untreated controls.
After 8 weeks of risperidone administration, distal femur trabec-
ular bone volume fraction (BV/TV) was 23% lower (pb0.01) than that
of untreated control mice (Fig. 2, Table 1). At this time point,
trabecular number and connectivity density were signiﬁcantly lower
while trabecular separation was signiﬁcantly higher than control. By
the ﬁfth week of treatment, risperidone treated mice had reduced
femur midshaft cortical thickness, which can be attributed to a
reduction in periosteal circumference compared to controls (Table 1).
After 8 weeks, however, the difference in periosteal circumference
was no longer evident, although risperidone-treated mice continued
to have signiﬁcantly lower percent Ct.Ar/Tt.Ar (Table 1).
Table 1
Male femur μCT after ﬁve and 8 weeks of risperidone treatment.
Five week treatment Eight week treatment
Control (n=8) Risperidone (n=8) Control (n=8) Risperidone (n=8)
Trabecular
BV/TV (%) 8.1±0.6 7.7±0.8 9.5±0.4 7.3±0.6⁎⁎
Tb.N (1/mm) 4.5±0.1 4.3±0.2 4.6±0.1 4.2±0.1⁎
Tb.Th (mm) 0.0379±0.0010 0.0378±0.0012 0.0401±0.0007 0.0383±0.0005
Tb.Sp (mm) 0.219±0.007 0.233±0.011 0.207±0.004 0.232±0.007⁎
Conn.D (1/mm3) 100±12 92±15 130±12 82±12⁎
Cortical
Tt.Ar (mm2) 1.96±0.03 1.84±0.02⁎⁎ 1.95±0.02 1.98±0.04
Ma.Ar (mm2) 1.12±0.02 1.07±0.01 1.05±0.01 1.09±0.02
Ct.Ar (mm2) 0.84±0.02 0.77±0.01⁎⁎ 0.90±0.01 0.89±0.02
Ct.Ar/Tt.Ar (%) 42.9±0.3 41.7±0.5⁎ 46.1±0.3 44.9±0.4⁎
Ct.Th (mm) 0.191±0.003 0.180±0.002⁎⁎ 0.204±0.002 0.201±0.002
Abbreviations: BV/TV, bone volume/total volume; Tb., trabecular; N, number; Th, thickness; Sp, separation; Conn.D, connectivity density; Tt., total; Ar, area; Ma, medullary; Ct.,
cortical.
⁎⁎ pb0.01 compared to age-matched control by two-tailed Student's t-test.
⁎ pb0.05 compared to age-matched control by two-tailed Student's t-test.
Table 2
Male static and dynamic tibia histomorphometry after ﬁve and 8 weeks of risperidone treatment.
Five week treatment Eight week treatment
Control Risperidone p value Control Risperidone p value
(n=6–8) (n=8) (n=7–8) (n=8)
BV/TV (%) 8.8±0.4 7.3±0.5⁎ 0.03 9.9±1.1 6.9±0.7⁎ 0.03
Tb.Th (μm) 29.9±1.2 27.2±1.0 0.10 31.3±1.2 28.5±0.9 0.09
Tb.N (/mm) 2.95±0.12 2.66±0.12 0.11 3.12±0.22 2.38±0.19⁎ 0.03
Tb.Sp (μm) 313±15 353±16 0.09 301±24 415±42⁎ 0.03
MS/BS (%) 27.7±4.2 23.2±2.1 0.32 26.3±2.5 27.6±2.3 0.71
MAR (μm/day) 2.03±0.09 2.11±0.18 0.72 1.18±0.08 1.02±0.07 0.15
BFR/BS (μm3/μm2/year) 199±24 180±22 0.57 113±14 103±13 0.61
BFR/BV (%/year) 1301±150 1273±146 0.90 706±61 741±113 0.78
BFR/TV (%/year) 117±17 92±10 0.21 76±14 49±7 0.13
Ob.S/BS (%) 5.2±1.1 6.5±1.3 0.43 2.3±0.6 3.0±1.0 0.53
N.Ob/T.Ar (/mm2) 26.2±4.9 28.9±4.9 0.70 12.2±3.2 11.2±3.0 0.81
N.Ob/B.Pm (/mm) 4.6±1.0 5.4±0.8 0.57 2.1±0.5 2.4±0.7 0.78
OV/TV (%) 0.044±0.011 0.047±0.011 0.89 0.012±0.004 0.015±0.006 0.63
OS/BS (%) 3.2±0.8 3.3±0.7 0.89 0.8±0.3 1.6±0.6 0.24
O.Th (μm) 2.1±0.3 2.5±0.2 0.35 2.7±0.4 1.6±0.4 0.08
Oc.S/BS (%) 2.5±0.6 5.7±0.9⁎ 0.01 1.5±0.3 2.9±0.5⁎ 0.02
N.Oc/T.Ar (/mm2) 6.4±1.6 11.8±1.2⁎ 0.02 3.3±0.6 5.2±0.9 0.11
N.Oc/B.Pm (/mm) 1.1±0.3 2.3±0.3⁎ 0.01 0.6±0.1 1.1±0.1⁎ 0.01
ES/BS (%) 0.98±0.20 2.56±0.38⁎ b0.01 0.53±0.14 0.93±0.27 0.21
Abbreviations: BV, bone volume; TV, tissue volume; Tb., trabecular; N, number; Th, thickness; Sp, separation; MS, mineralizing surface; BS, bone surface; MAR, mineral apposition
rate; BFR, bone formation rate; Ob.S, osteoblast surface; N.Ob, number of osteoblasts; T.Ar, tissue area; B.Pm, bone perimeter; OV, osteoid volume; OS, osteoid surface; O.Th, osteoid
thickness; Oc.S, osteoclast surface; N.Oc, number of osteoclasts; ES, eroded surface.
⁎ pb0.05 by two-tailed Student's t-test.
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Static and dynamic histomorphometry was performed on trabec-
ular bone of the proximal tibia in order to determine how risperidone
altered remodeling. Consistent with femur μCT results, after 8 weeks
of treatment, trabecular BV/TV and trabecular number were signiﬁ-
cantly lower in the risperidone treated group compared to untreated
controls (Table 2). Additionally, the reduction in BV/TV was also
statistically signiﬁcant in the tibia by 5 weeks of treatment, which was
not apparent in the femur μCT. Neither treatment period signiﬁcantly
altered measurements of mineralization, bone formation, or osteo-
blast numbers. However, risperidone treated mice did have signiﬁ-
cantly elevated bone resorption parameters, at both ﬁve and 8 weeks
of treatment, including percent of bone surface in contact with
osteoclasts and number of osteoclasts per unit bone surface. Erosion
surface was also 2.5-fold higher in mice treated with risperidone for
5 weeks compared to control mice. This difference was not statisti-
cally detectable at the eight-week time point. Bone marrow adipocyte
number was not signiﬁcantly different after ﬁve or 8 weeks of oral
risperidone administration vs control treated animals (not shown).
In order to further investigate adipose tissue changes observed by
DXA, we examined abdominal and subcutaneous fat by MRI.
Representative MR images demonstrate that both subcutaneous and
visceral fats were reduced after 5 weeks of risperidone treatment
(Fig. 3A). This reduction in mass of normal white adipose tissue
depots was coupled with an increase in liver adiposity as measured by
Oil Red O staining and by weight measurements (Fig. 3B).
Given the potential variability due to food supplementation, we
measured risperidone and 9-OH risperidone levels in the serum of
mice at each time point. Although risperidone levels were low to
undetectable by mass spectrometry (likely due to the overnight fast
and therefore no new drug exposure), the more stable 9-OH
risperidone was detectable at levels of 7.9±3.5 ng/ml (range 1.6–
24.1 ng/ml) for the ﬁve week treatment and 6.0±0.8 ng/ml (range
4.6-9.3 ng/ml) for the eight week treatment, which are within the
range obtained in human patients [23–25].
Subcutaneous risperidone infusion
Due to variability in the amount of risperidone delivered per
mouse by food supplementation, we administered risperidone
(0.5 mg/kg per day) to 7-week old C57BL/6 J mice via subcutaneous
osmotic minipumps for 28 days. In the literature, female mice are
more likely to have a weight-gain side effect of SGA administration;
therefore we used female mice instead of males to try to exclude
weight loss as a confounding factor in the bone effects we observed
with male mice. At two and 4 weeks after pump implantation, serum
risperidone concentration was 5.9±0.7 ng/ml (range 5.0–7.9 ng/ml)
and 1.3±0.3 ng/ml (range 0.8–2.3 ng/ml), respectively. The concen-
tration of 9-OH risperidonewas 3.8±0.5 ng/ml (range 2.8–5.7 ng/ml)
at 2 weeks and 2.4±0.3 ng/ml (range 1.5–3.1 ng/ml) at 4 weeks,
whichwas considerably less variable than levels measured during oral
administration.
Mice did not have signiﬁcantly altered body mass, fat mass or lean
mass after infusion of risperidone (Fig. 4A). Additionally, insulin
tolerance (Fig. 4B) and glucose tolerance (Fig. 4C) were not different
between treatment groups. Similar to oral administration, whole body
aBMD was not different between groups. Despite the shortened
treatment duration and lower dose, femur aBMD was lower in mice
treated with risperidone compared to control (Fig. 4D). Both distal
femur trabecular BV/TV and connectivity density were signiﬁcantly
reduced (44% and 64%, respectively) (Table 3). Cortical thickness,
cortical area and percent of the total area were also lower in the femur
of risperidone treated mice compared to control.
Serum P1NP, a marker of bone formation, was lower in risperidone
treated mice while there was no difference in CTx, a marker of
resorption (Fig. 4E). Consistent with these data, histomorphometric
analysis of the tibia in 7 week old mice treated with subcutaneous
risperidone infusion revealed signiﬁcantly suppressed MAR (de-
creased 18%) and BFR/BV (decreased 34%). In addition, osteoblast
number was markedly reduced (p=0.05) and there was a 53%
increase in osteoclast number although it did not reach statistical
signiﬁcance (p=0.12) (Table 4).
Direct effect of risperidone on osteoclast differentiation
In order to determine whether the effects of risperidone on
resorption parameters could be due to direct interaction with
osteoclasts, we cultured primary osteoclasts from bone marrow in
the presence or absence of risperidone. Addition of both 2.5 and
25 ng/ml risperidone with each media change increased TRAP
positive osteoclast number in a dose dependent manner (Fig. 5). On
the other hand, when bone marrow stromal cells were exposed to
risperidone in vitro, there were no differences in osteoblast prolifer-
ation or differentiation compared to untreated cells (data not shown).
Discussion
In this paper we have clearly established that risperidone has a
negative impact on bone mass in mice and that this effect may be due
to both direct and indirect mechanisms. Using both male and female
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mice, and both oral administration and subcutaneous infusion, we
found that risperidone reduces both trabecular and cortical bone
mass, and that this effect is likely due to imbalanced bone remodeling
(Table 2). Interestingly, both modes of administration of risperidone
reduced bone mass but histomorphometric analyses revealed there
were differentmechanisms of action for risperidone. For example, oral
risperidone treatment was associated with a primary increase in bone
resorption with little change in bone formation, whereas subcutane-
ous infusion of risperidone resulted in a reduction in P1NP (Fig. 4B)
and suppression of both bone formation and mineral apposition
rates. These data suggest there may be both cell autonomous (i.e. on
osteoclasts) and non-cell autonomous effects (i.e. on osteoblasts)
since in vitro studies could not demonstrate signiﬁcant changes in the
pace of osteoblast differentiation in response to risperidone.
However, it should be noted that only 7-week-old female mice
were administered subcutaneous risperidonewhereas only 3.5-week-
old male mice were treated with the oral form. At 7 weeks of age,
female B6 mice are near their peak in trabecular number and
trabecular BV/TV in the distal femur [26]. Thereafter, trabecular BV/
TV in the distal femur declines due to enhanced resorption relative to
formation. Risperidone treatment accelerated trabecular bone loss in
B6 females by further suppressing bone formation. Male B6 mice gain
trabecular BV/TV and number up to 8 weeks of age, thus during the
ﬁrst treatment period (3.5 to 8.5 weeks of age) normal modeling
favors bone formation, whereas during the second period (8.5 to 11.
5 weeks of age) modeling tends to favor resorption [26]. Therefore,
from 3.5 to 8.5 weeks of age, trabecular bone mass in the risperidone
treated animals is likely unable to reach its peak due to elevated
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resorption compared to B6 controls. During the remainder of the
treatment time (i.e. 8.5 to 11.5 weeks), formation and resorption
begin to decrease, but resorption in the risperidone treated mice does
not decrease to the level of the control mice. This effect, coupled to the
inability of risperidone administered mice to reach peak trabecular
bone mass, contributes to the greater % trabecular BV/TV reduction
observed in the mice with longer risperidone exposure. Thus, gender
differences, age differences, levels of risperidone achieved, as well as
the direct and indirect effects of the drug on bone cells contribute to
the skeletal response to this drug. Notwithstanding these confounding
variables, it is clear that bone loss occurs with risperidone treatment
of mice, independent of weight gain.
At aﬁrst glance, hyperprolactinemiawould be anothermechanismof
bone loss secondary to risperidone, which is a dopamine receptor
antagonist [11,12]. However, there is controversy about risperidone-
inducedhyperprolactinemia andwewereunable to showanelevation in
serum prolactin with either type of risperidone administration.
Furthermore, female mice subjected to risperidone treatment did not
show uterine atrophy that would be expected with hypogonadism (not
shown).While there are data suggesting that high PRL levels are a long-
term complication of risperidone treatment [27,28], others indicate that
its occurrence is a transient side effect [18]. Therefore, an alternative
mechanism likely exists for the profound alterations in bone turnover
that we observed.
In addition to its actions as a dopaminergic antagonist, risperidone
also has anti-serotonergic effects. Recently, serotonin was found to be a
crucial intermediate molecule in the regulation of bone mass by leptin
[29,30]. Leptin modulates bone metabolism indirectly through the
hypothalamus by activating the sympathetic nervous system (SNS),
thereby suppressing bone formation while stimulating bone resorption
via skeletal beta adrenergic receptors on osteoblasts [31,32]. Leptin-
deﬁcient ob/ob mice show increased cancellous spine bone mass and
overt obesity in spite of hypogonadism and elevated cortisol levels [33].
The pattern of bone changes in leptin-deﬁcient mice may be reproduced
by a chemical lesion of neurons in the region of the ventromedial
hypothalamus [34]. However, another component of the central action of
leptin emerged recently, when it was demonstrated that leptin receptor
in hypothalamic ventromedial neurons is not essential to trigger leptin
action [35]. Likely, leptin acts in other sites of the brain to regulate bone
remodeling. Serotonergic neurons of the brainstem are a reasonable
candidate to mediate this action, particularly since the consequences of
leptin deﬁciency on bone turnover can be reversed by hampering
serotonin production in the brainstem. Mice deﬁcient in brain-derived
production of serotonin (Tph2−/−) exhibit the opposite phenotype of
leptin-deﬁcient mice. Notably, Tph2−/−mice have decreased bone mass
associated to low bone formation and increased bone resorption, albeit
they exhibit normal levels of leptin [36]. Thus, it is plausible that the
sympathetic nervous system activitymay be elevated during risperidone
administration and this may contribute to the non-cell autonomous
effects on osteoblasts observed with subcutaneous administration.
Table 3
Female tibia μCT after 4 weeks of risperidone infusion.
Osmotic minipumps p value
Saline (n=5) Risperidone (n=5)
Trabecular
BV/TV (%) 4.3±0.6 2.4±0.3⁎ 0.02
Tb.N (1/mm) 3.1±0.2 2.9±0.1 0.07
Tb.Th (mm) 0.036±0.002 0.033±0.001 0.15
Tb.Sp (mm) 0.322±0.017 0.359±0.007 0.08
Conn.D (1/mm3) 28±7 10±2⁎ 0.03
Cortical
Tt.Ar (mm2) 1.73±0.01 1.67±0.03 0.14
Ma.Ar (mm2) 0.98±0.01 0.99±0.02 0.56
Ct.Ar (mm2) 0.75±0.01 0.68±0.02⁎ 0.03
Ct.Ar/Tt.Ar (%) 43.2±0.5 40.6±0.5⁎ 0.02
Ct.Th (mm) 0.182±0.003 0.168±0.004⁎ 0.02
Abbreviations: BV/TV, bone volume fraction; Tb., trabecular; N, number; Th, thickness;
Sp, separation; Conn.D, connectivity density; Tt., total;Ar, area;Ma,medullary; Ct., cortical.
⁎ pb0.05 by two-tailed Student's t-test.
Table 4
Female static and dynamic histomorphometry after 4 weeks of risperidone infusion.
Osmotic minipumps p value
Saline (n=4–5) Risperidone (n=4–5)
BV/TV (%) 5.1±1.1 3.7±0.9 0.34
Tb.Th (μm) 32.7±2.5 30.4±1.9 0.49
Tb.N (/mm) 1.50±0.26 1.15±0.24 0.34
Tb.Sp (μm) 775±217 1230±494 0.42
MS/BS (%) 30.4±3.1 27.4±2.8 0.49
MAR (μm/day) 2.96±0.04 2.42±0.10⁎ b0.01
BFR/BS (μm3/μm2/year) 329±32 241±25 0.08
BFR/BV (%/year) 2181±241 1436±167⁎ 0.04
BFR/TV (%/year) 95±20 58±18 0.22
Ob.S/BS (%) 6.6±1.5 2.0±1.4 0.05
N.Ob/T.Ar (/mm2) 15.5±5.2 4.8±3.1 0.12
N.Ob/B.Pm (/mm) 5.4±1.4 1.5±1.0 0.05
OV/TV (%) 0.003±0.003 0.002±0.001 0.82
OS/BS (%) 0.26±0.26 0.46±0.29 0.62
O.Th (μm) 0.69±0.69 0.75±0.46 0.95
Oc.S/BS (%) 2.9±0.7 4.4±0.9 0.19
N.Oc/T.Ar (/mm2) 3.1±0.8 4.2±1.1 0.43
N.Oc/B.Pm (/mm) 1.1±0.2 1.7±0.2 0.12
ES/BS (%) 1.49±0.42 1.86±0.39 0.53
N.Ad/T.Ar (/mm2) 7.9±1.5 32.5±10.0 0.07
Abbreviations: BV, bone volume; TV, tissue volume; Tb., trabecular; N, number; Th,
thickness; Sp, separation; MS, mineralizing surface; BS, bone surface; MAR, mineral
apposition rate; BFR, bone formation rate; Ob.S, osteoblast surface; N.Ob, number of
osteoblasts; T.Ar, tissue area; B.Pm, bone perimeter; OV, osteoid volume; OS, osteoid
surface; O.Th, osteoid thickness; Oc.S, osteoclast surface; N.Oc, number of osteoclasts;
ES, eroded surface; N.Ad, number of adipocytes.
⁎ pb0.05 by two-tailed Student's t-test.
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Ota et al. also demonstrated that rats treated with risperidone are
resistant to weight gain [37,38]. These authors attributed this observa-
tion to increased energy expenditure as suggested by the enhanced gene
expression of Ucp1 in brown adipose tissue, and Ucp3, β1 adrenergic
receptor and lipolytic enzymes in white adipose tissue. In accordance
with the Ota results, our risperidone-treated mice did not show an
obesity phenotype. Moreover, the present study shows that risperidone
treatment was associated with increased fat deposition within the liver.
This occurrence might reﬂect increased lipolysis in visceral adipose
tissue, which promptly releases free fatty acids into the portal system, or
maybe due to a generalized redistribution of fatmass. However,we only
demonstrated a non-signiﬁcant increase in marrow adiposity in the
subcutaneously infused mice (p=0.07) and no change in marrow
adiposity in the orally administered mice. Taken together, the evidence
from histomorphometry, bone turnover markers and μCT in risperidone
treatedmice prevent us from excluding a non-cell autonomous effect on
bone remodeling due to increased sympathetic nervous system activity.
In our study and other rodent SGA studies, risperidone treated mice
didnot gainweightas is oftenobserved inhumanclinical trials.However,
it is necessary to take into account that the circumstances of our
experiments are different from those observed in clinical investigation.
Different psychiatric disorders (i.e., anorexia nervosa, schizophrenia and
depression) have diverse impacts on body weight and eating behavior,
probably reﬂecting typical alteration on brain physiology [30,39,40].
Thus, it can be hypothesized that the impact of drugs, with actions on
neuromodulators, or on eating behavior in individuals can be different
from that observed in conditions of psychiatric disorders.
Despite clear evidence for a mechanism of risperidone affecting bone
metabolism indirectly through the central nervous system, we did
observe increased osteoclast differentiation with direct risperidone
administration in vitro (Fig. 5). Osteoclasts express serotonin receptors
and others that are potential targets for risperidone. Moreover, the in
vitro changes in osteoclast differentiation are consistent with the in vivo
histomorphometric data when mice are administered oral risperidone.
However, as noted, we cannot exclude that there is a non-cell
autonomous effect of risperidone on osteoblasts that stimulates RANKL
and subsequently causes increased bone resorption. One possibility is
that this is sympathetically mediated. Another possible mechanism is
that risperidoneactivates PPARγwhich can suppress bone formation and
enhance osteoclastogenesis. Interestingly, in the mice treated by
minipump, there was a four-fold increase in marrow adipocytes
(p=0.07) that was not seen with oral administration.
In conclusion, the present data show that risperidone impacts bone
remodeling inmice by acting on resorption and formation in both a cell
autonomous and non-cell autonomous manner. Consequently, we
observed decreased bone mass and altered bone microarchitecture. In
addition to reduced fat mass, risperidone therapy was associated with
enlarged fatty liver. Thus, in addition to risperidone therapy creating
conditions that could affect the central regulation of bone mass, the
present study mandates that further clinical studies be focused on its
direct effects on bone turnover, particularly in adolescents when peak
bone mass is being acquired.
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